Business Description
Mesoblast Ltd
NAICS : 541711
ISIN : AU000000MSB8
Share Class Description:
ASX:MSB: Ordinary SharesCompare
Compare
Traded in other countries / regions
MSB.AustraliaMESO.USALWB.Germany IPO Date
2004-12-16Description
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.53 | |||||
| Equity-to-Asset | 0.72 | |||||
| Debt-to-Equity | 0.25 | |||||
| Debt-to-EBITDA | -6.97 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -15.7 | |||||
| 3-Year EBITDA Growth Rate | 18 | |||||
| 3-Year EPS without NRI Growth Rate | 21.4 | |||||
| 3-Year FCF Growth Rate | 29.4 | |||||
| 3-Year Book Growth Rate | -17.1 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 238.38 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 51.2 | |||||
| 9-Day RSI | 47.74 | |||||
| 14-Day RSI | 46.9 | |||||
| 6-1 Month Momentum % | 145.57 | |||||
| 12-1 Month Momentum % | 122.4 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.18 | |||||
| Quick Ratio | 1.18 | |||||
| Cash Ratio | 0.85 | |||||
| Days Sales Outstanding | 313 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -18.6 | |||||
| Shareholder Yield % | -10.34 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -876.09 | |||||
| Net Margin % | -1024.76 | |||||
| FCF Margin % | -1752.59 | |||||
| ROE % | -4.39 | |||||
| ROA % | -3.26 | |||||
| ROIC % | -3 | |||||
| 3-Year ROIIC % | 52.84 | |||||
| ROC (Joel Greenblatt) % | -343.44 | |||||
| ROCE % | -2.92 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio without NRI | 0.08 | |||||
| PEG Ratio | 0.01 | |||||
| PS Ratio | 233.75 | |||||
| PB Ratio | 1.47 | |||||
| EV-to-EBIT | -43.58 | |||||
| EV-to-EBITDA | -45.92 | |||||
| EV-to-Revenue | 370.51 | |||||
| EV-to-Forward-Revenue | 17.13 | |||||
| EV-to-FCF | -20.63 | |||||
| Earnings Yield (Greenblatt) % | -2.29 | |||||
| FCF Yield % | -5.09 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mesoblast Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 3.187 | ||
| EPS (TTM) (A$) | -3.978 | ||
| Beta | 2.24 | ||
| Volatility % | 124.89 | ||
| 14-Day RSI | 46.9 | ||
| 14-Day ATR (A$) | 0.046521 | ||
| 20-Day SMA (A$) | 0.974 | ||
| 12-1 Month Momentum % | 122.4 | ||
| 52-Week Range (A$) | 0.255 - 1.33 | ||
| Shares Outstanding (Mil) | 1,141.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mesoblast Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mesoblast Ltd Stock Events
| Event | Date | Price(A$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Mesoblast Ltd Frequently Asked Questions
What is Mesoblast Ltd(ASX:MSB)'s stock price today?
The current price of ASX:MSB is A$0.96. The 52 week high of ASX:MSB is A$1.33 and 52 week low is A$0.26.
When is next earnings date of Mesoblast Ltd(ASX:MSB)?
The next earnings date of Mesoblast Ltd(ASX:MSB) is 2024-10-30 Est..
Does Mesoblast Ltd(ASX:MSB) pay dividends? If so, how much?
Mesoblast Ltd(ASX:MSB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers